Hypha Labs (Hypha Labs) Cash And Cash Equivalents : $0.31 Mil (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Hypha Labs Cash And Cash Equivalents?

Hypha Labs's quarterly cash and cash equivalents declined from Jun. 2023 ($0.33 Mil) to Sep. 2023 ($0.27 Mil) but then increased from Sep. 2023 ($0.27 Mil) to Dec. 2023 ($0.31 Mil).

Hypha Labs's annual cash and cash equivalents declined from Sep. 2021 ($0.30 Mil) to Sep. 2022 ($0.06 Mil) but then increased from Sep. 2022 ($0.06 Mil) to Sep. 2023 ($0.27 Mil).

Hypha Labs Cash And Cash Equivalents Historical Data

The historical data trend for Hypha Labs's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hypha Labs Cash And Cash Equivalents Chart

Hypha Labs Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.32

0.08

0.30

0.06

0.27

Hypha Labs Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															0.16	0.12	0.33	0.27	0.31

Hypha Labs Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Hypha Labs (OTCPK:DIGP) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Hypha Labs Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Hypha Labs's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Hypha Labs (Hypha Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hypha Labs Inc (OTCPK:DIGP) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

6450 Cameron Street, Suite 113, Las Vegas, NV, USA, 89118

Website

https://www.digipath.com

DigiPath Inc is engaged in providing pharmaceutical-grade analysis and testing cannabis education and training and brings unbiased cannabis news coverage to the cannabis industry. It screens medicinal cannabis for potentially harmful contaminants, including solvents, pesticides, mold and yeast, heavy metals such as mercury, arsenic, cadmium, and others. It also tests cannabis for its quality, potency, and cannabinoid and terpene profiles, which determine the suitability of specific cannabis strains for the treatment of specific ailments.

Executives

A Stone Douglass	director	10200 WILLOW CREEK ROAD, SAN DIEGO CA 92131
Edmond Defrank	director	19360 RINALDI STREET, #448, NORTHRIDGE CA 91326
Kyle Remenda	officer: Chief Executive Officer	111-2532 SHORELINE DRIVE, LAKE COUNTRY A1 V4V2R6
Dennis Hartmann	director	1600 CAMDEN AVENUE, NO. 103, LOS ANGELES CA 90025
Bruce I Raben	director	430 VICTORIA TERRACE, RIDGEFIELD NJ 7657
Cindy Sue Orser	director	4507 APPLE WAY, BOULDER CO 80301
Alfredo Axtmayer	director	287 PAYNE DRIVE, CHESHIRE CT 06410
Joseph J Bianco	director	611 BROADWAY,, SUITE 307, NEW YORK NY 10012
Todd A Peterson	officer: Chief Financial Officer	3608 MALLARDWOOD DRIVE, LAS VEGAS NV 89129
Joe D Tanner	director	28720 ROADSIDE DRIVE, SUITE 128, AGOURA HILLS CA 91301
Raw Alternative, Llc	10 percent owner	16030 VENTURA BLVD. SUITE 380, ENCINO CA 91436
Todd Denkin	director, officer: President	C/O PHOTOTRON, INC., 20259 VENTURA BLVD., WOODLAND HILLS CA 91364
Barbee Denny Barbee	10 percent owner	3105 EAST CENTRAL, #114, WICHITA KS 67214
Eric Stoppenhagen	director, 10 percent owner, officer: CFO	8908 SPLITARROW DRIVE, AUSTIN TX 78717